Eculizumab in kidney diseases

The C5 inhibitor monoclonal antibody, eculizumab, has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); however, efficacy safety this drug in treating other complement-related renal diseases not yet elucidated. high cost eculizumab therapy rare adverse effects have created a paradox conducting large clinical trials. Therefore, there is need to increase clinicians’ awareness available data on efficacy/safety diseases. Herein, we reviewed outcomes administration aHUS, PNH, lupus erythematosus nephritis, C3 glomerulonephritis, IgA nephropathy, antibody-mediated rejection (AMR) highly sensitized patients. Initial findings suggest its acute injuries but lower effectiveness preventing chronic lesions. Besides, early diagnosis timely initiation are particular importance.